$IRD

Magrath George sold $28K of IRD

Magrath George (Chief Executive Officer) sold 9,475 shares of Opus Genetics, Inc. (IRD) at $2.95 on 2026-07-23.

Original reporting
SEC EDGAR · Magrath George
Published Jul 27, 2026, 8:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRD
Neutral
medium confidence
Mentioned
$IRD
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRDNeutralLow
01

Why it matters

Traders may monitor for clustering of insider sales or follow-on disclosures, but this specific filing does not provide new operational or financial guidance.

02

Market read

A CEO open-market sale of $27.9K is disclosed, which may slightly affect sentiment but is unlikely to drive fundamentals.

03

What to watch

The absence of a stated 10b5-1 plan may raise speculation, but Form 4s can still reflect pre-planned trading or routine compensation-related activity not captured here.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-27 after-hours; reflects sale executed 2026-07-23.

Background

The article is an SEC Form 4 insider transaction disclosure for Opus Genetics, Inc.

Company-level read

Ticker impact

$IRDNeutralMedium confidence
Context

Opus Genetics CEO Magrath George sold 9,475 shares on 2026-07-23 at $2.9473, totaling $27,925.67, per Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no earnings, guidance, deal, or operational update. Insider sales can be non-informational, and the disclosed value is relatively small.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or personal liquidity needs, especially given the small dollar amount and lack of any accompanying negative corporate event.

Key entities

  • Opus Genetics, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Magrath George

    CEO and officer/director who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRDMed

Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics (Nasdaq: IRD) reported Q2 2026 results for the quarter ended June 30, 2026. Cash was $88.8 million, expected to fund operations into 2029. Revenue fell to $0.8 million from $2.9 million. R&D rose to $11.2 million. Net loss was $8.1 million. The company also updated clinical timelines for OPGx-BEST1, OPGx-LCA5, and other programs.

$IRDMed

Opus Genetics, Inc.: Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Opus Genetics (Nasdaq: IRD) updated its OPGx-BEST1 Phase 1/2 trial (BIRD-1) for BEST1-associated inherited retinal diseases. Cohort 1 enrollment (5 participants) is complete, with Month 3 data expected in the second week of September 2026. The company plans to present at EURETINA in October 2026 and submit Month 3 results to the FDA for next steps.